Resilience, a contract development and manufacturing organization specializing in pharmaceutical production, has expanded its strategic partnership with Eli Lilly and Company to increase U.S. production of critical medicines featuring new pharmaceutical manufacturing investments in Ohio.
Building on a partnership first established in 2023, $750 million of investment by Resilience and Lilly has expanded Resilience’s advanced manufacturing operations in the Cincinnati region, which will now include Lilly’s KwikPen injectable device for innovative medicines treating diabetes and obesity. The addition of KwikPen production will create at least 400 new jobs, bringing total Resilience-created jobs in Ohio to more than 1,400 across its facilities. Site preparation for the campus expansion is underway, with full operations expected to commence in early 2027.
The multi-year manufacturing partnership between Lilly and Resilience has already produced more than 150 million doses of medicines for patients in the United States in vial and pre-filled syringe formats. Together, the companies have established one of the nation’s largest sterile injectable manufacturing operations, demonstrating how trusted U.S. manufacturing partnerships can rapidly scale production while maintaining the highest levels standards of quality, reliability, and execution.
Resilience currently operates two advanced facilities in the Cincinnati region that together comprise nearly 1 million square feet and employ nearly 1,000 Resilience team members across manufacturing, operations, quality, and regulatory functions. The company recently announced the establishment of its Blue Ash, Ohio location as its global headquarters, evidencing its long-term commitment to the state.
